glp-1 drugs pharmaceutical companies news 2025 health pharma today obesity october Outlook for obesity in 2025: more GLP-1 Antagonists Increase Plan Drug
Description
Until 2026, almost every effective option required weekly injections
Clinical trials have revealed that retatrutide can reduce markers of inflammation, such as C-reactive protein (CRP), which are associated with an increased risk of cardiovascular disease
Semaglutide is known as a glucagon-like peptide-1 (GLP-1) receptor agonists
The most cost-effective approach may be a combination strategy
L.KennedyN
Obesity is more prevalent among low-income Rhode Islanders and communities of color
